Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Immunology

Figure 2

From: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity

Figure 2

Time schedule of re-challenge with 5 × 105viable B16F1 tumor cells of pre-vaccinated mice surviving the first tumor challenge. * vaccination started 90 days before the first injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval ** vaccination started 60 days before the first injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval *** vaccination started 30 days before the first injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) in 15 days interval or three times (3×) in 15 days interval, except for the last vaccination, which was performed 7 days after second vaccination.

Back to article page